UCB SA (OTCMKTS:UCBJY – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $100.01 and last traded at $99.97, with a volume of 9355 shares trading hands. The stock had previously closed at $97.35.
UCB Trading Up 2.7 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company has a fifty day moving average of $95.55 and a 200 day moving average of $87.64.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- What Are Treasury Bonds?
- Dow Jones: A Relevant Benchmark or a Relic of the Past?
- What is an Earnings Surprise?
- 3 Big-Name Stocks Just Announced Big-Time Dividend Increases
- Trading Stocks: RSI and Why it’s Useful
- Market Overreaction: 2 Stocks to Buy on the Way Down
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
